drugset / Trial / NCT03006029
Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms
NaSingle-groupOpen-labelOther
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose of TAB08 when administered intravenously (i.v.) to patients with advanced solid malignancies.
Timeline
- Start
- 2017-02-08
- Primary completion
- 2019-05-14
- Completion
- 2019-08-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TGN-1412 | Monoclonal antibody | 1 ug/kg | Intravenous |